Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 9:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–17 of 17 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Brimonidine Tartrate Ophthalmic Solution 0.2% Clear all

Conditions: Open-angle Glaucoma, Ocular Hypertension
Interventions: Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, Brinzolamide/brimonidine vehicle, Travoprost 0.004%/timolol 0.5% solution; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Glaucoma, Ocular Hypertension
Interventions: Brimonidine 0.2%/Timolol 0.5% Fixed Combination Ophthalmic Solution, Concurrent brimonidine 0.2% and 0.5% timolol; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 604 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Glaucoma, Ocular Hypertension
Interventions: 0.1% brimonidine tartrate ophthalmic solution, 0.01% bimatoprost ophthalmic solution, 0.2% hypromellose lubricant eye drops, latanoprost 0.005% ophthalmic solution; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Deerfield Beach, Florida

Conditions: Erythematous Rosacea
Interventions: 0.18% COL-118 facial gel (1.8 mg brimonidine), 0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop), Advanced Eye Relief, COL-118 facial gel vehicle; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Broomall, Pennsylvania

Conditions: Intraoperative Floppy Iris Syndrome
Interventions: Brimonidine Tartrate; Drug
Lead sponsor: Denver Health and Hospital Authority; Other
Eligibility: 18 Years to 100 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Glaucoma, Ocular Hypertension
Interventions: fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution; bimatoprost 0.03% ophthalmic solution, bimatoprost 0.03% ophthalmic solution; hypromellose 0.2% eyedrops; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Open Angle Glaucoma
Interventions: Simbrinza 0.2%-1% Ophthalmic Suspension, Rocklatan 0.02%-0.005% Ophthalmic Solution, Cosopt PF 2%-0.5% Ophthalmic Solution, Latanoprost 0.005% Ophthalmic Solution; Drug
Lead sponsor: Prairie Eye Center; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Springfield, Illinois

Conditions: Glaucoma, Ocular Hypertension
Interventions: Fixed-Combination Bimatoprost/Brimonidine, Bimatoprost Ophthalmic Solution 0.01%, Vehicle Ophthalmic Solution, Brimonidine Tartrate Ophthalmic Solution 0.2%; Drug
Lead sponsor: Allergan; Industry
Eligibility: 40 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Glaucoma, Glaucoma, Open-Angle, Glaucoma; Drugs, Droopy Eyelid, Ptosis, Glaucoma, Primary Open Angle
Interventions: brimonidine tartrate ophthalmic solution 0.025%, sterile balanced saline solution; Drug · Other
Lead sponsor: Tulane University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2036
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Open-Angle Glaucoma, Ocular Hypertension
Interventions: Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension, Brinz/brim vehicle, Prostaglandin analogue; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Dry Eye
Interventions: Brimonidine, Brimonidine Mono Therapy, sodium carboxymethylcellulose, Corticosteroid Eye Drop; Drug
Lead sponsor: Ocugen; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 3
States / cities: Hoffman Estates, Illinois • Yorkville, Illinois • Salt Lake City, Utah

Conditions: Glaucoma, Ocular Hypertension
Interventions: fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution, latanoprost 0.005%; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Slingerlands, New York

Conditions: Glaucoma, Ocular Hypertension
Interventions: Brimonidine ophthalmic solution 0.1%, Brimonidine ophthalmic solution 0.2%; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 433 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Glaucoma
Interventions: fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution, fixed combination of dorzolamide hydrochloride timolol maleate ophthalmic solution; Drug
Lead sponsor: Allergan; Industry
Eligibility: 30 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Glaucoma, Ocular Hypertension
Interventions: 0.2% brimonidine/0.5% timolol fixed combination ophthalmic solution, Concurrent brimonidine 0.2% and Timolol 0.5% ophthalmic solution, Brimonidine 0.2% ophthalmic solution; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 432 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: El Paso, Texas

Conditions: Dry Eye
Interventions: Brimonidine Tartrate, Placebos; Drug
Lead sponsor: Ocugen; Industry
Eligibility: 18 Years and older
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 16
States / cities: Newport Beach, California • Rancho Cordova, California • Pompano Beach, Florida + 11 more

Conditions: Glaucoma; Drugs, Normal Tension Glaucoma, Primary Open-angle Glaucoma
Interventions: Timolol Maleate, Brimonidine Tartrate; Drug
Lead sponsor: Wills Eye; Other
Eligibility: 18 Years to 90 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV®

Study to Evaluate Safety of Brimonidine/Timolol Fixed Combination in Glaucoma or Ocular Hypertension Patients

A Safety and Efficacy Study of ALPHAGAN® P and LUMIGAN® in Subjects Previously Treated With Latanoprost for Glaucoma and Ocular Hypertension

Systemic Bioavailability Study Of Col-118 Administered Topically as a 0.18 % Facial Gel And Brimonidine Ophthalmic Solution 0.2%

Pupil Dilation for Treatment of IFIS

Comparing Safety and Efficacy of Combigan® and Lumigan® With Lumigan® Alone in Glaucoma or Ocular Hypertension Subjects Treated With Xalatan®

Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost

A Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in Chronic Glaucoma or Ocular Hypertension

The Effect of Lumify™ on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients

SIMBRINZA® Suspension BID as an Adjunctive to Prostaglandin Analogue (PGA)

Dry Eye Disease Study With Brimonidine

An Evaluation of the Fixed Combination Brimonidine Tartrate 0.2%/ Timolol Maleate 0.5% to Latanoprost 0.005% in Glaucoma or Ocular Hypertension Subjects

Safety and Efficacy Study of Brimonidine in Patients With Glaucoma or Ocular Hypertension

Comparing Effects of Two Fixed Combinations Ophthalmic Solutions on Ocular Blood Flow

Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension

Study of Brimonidine Tartrate Nanoemulsion Eye Drop Solution in the Treatment of Dry Eye Disease (DED)

Peripapillary Blood Flow After Use of Anti-glaucoma Medications: An OCT Angiography Study